加载中…
Anti-CD20 Antibody (Rituximab Biosimilar) is a research-use biosimilar antibody expressed in HEK293. The source page specifies target CD20, reactivity Human, isotype Human IgG1-Kappa, source-listed application ELISA/SPR/BLI.
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R, CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
